Dimensional Fund Advisors LP reduced its stake in shares of Mylan (NASDAQ:MYL) by 1.7% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 4,487,787 shares of the company’s stock after selling 79,284 shares during the period. Dimensional Fund Advisors LP owned approximately 0.87% of Mylan worth $184,762,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in MYL. HM Payson & Co. grew its stake in shares of Mylan by 7.3% during the 4th quarter. HM Payson & Co. now owns 21,938 shares of the company’s stock worth $928,000 after acquiring an additional 1,498 shares in the last quarter. Envestnet Asset Management Inc. grew its stake in shares of Mylan by 23.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 8,283 shares of the company’s stock worth $349,000 after acquiring an additional 1,596 shares in the last quarter. Natixis Advisors L.P. grew its stake in shares of Mylan by 2.6% during the 1st quarter. Natixis Advisors L.P. now owns 70,253 shares of the company’s stock worth $2,892,000 after acquiring an additional 1,781 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. grew its stake in shares of Mylan by 25.4% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,080 shares of the company’s stock worth $384,000 after acquiring an additional 1,840 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. grew its stake in shares of Mylan by 5.4% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 37,573 shares of the company’s stock worth $1,547,000 after acquiring an additional 1,929 shares in the last quarter. Hedge funds and other institutional investors own 83.66% of the company’s stock.

Mylan opened at $38.46 on Friday, Marketbeat.com reports. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.06 and a quick ratio of 0.65. Mylan has a one year low of $29.39 and a one year high of $47.82. The firm has a market cap of $19.94 billion, a price-to-earnings ratio of 8.43, a P/E/G ratio of 1.26 and a beta of 1.35.

Mylan (NASDAQ:MYL) last released its quarterly earnings data on Wednesday, May 9th. The company reported $0.96 EPS for the quarter, missing the Zacks’ consensus estimate of $0.99 by ($0.03). Mylan had a return on equity of 18.56% and a net margin of 6.04%. The company had revenue of $2.68 billion for the quarter, compared to the consensus estimate of $2.74 billion. During the same period last year, the firm earned $0.93 earnings per share. The company’s revenue for the quarter was down 1.3% compared to the same quarter last year. sell-side analysts anticipate that Mylan will post 5.36 earnings per share for the current fiscal year.

In other Mylan news, insider Paul Campbell sold 7,030 shares of Mylan stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $44.01, for a total transaction of $309,390.30. Following the completion of the transaction, the insider now directly owns 17,054 shares of the company’s stock, valued at $750,546.54. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Robert J. Coury sold 50,000 shares of Mylan stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $43.41, for a total transaction of $2,170,500.00. The disclosure for this sale can be found here. Insiders own 0.69% of the company’s stock.

Several brokerages have recently weighed in on MYL. Wells Fargo & Co set a $41.00 price target on shares of Mylan and gave the stock a “hold” rating in a research note on Thursday. BidaskClub raised shares of Mylan from a “sell” rating to a “hold” rating in a research note on Wednesday, May 16th. JPMorgan Chase & Co. set a $53.00 price target on shares of Mylan and gave the stock a “buy” rating in a research note on Wednesday, May 23rd. Cantor Fitzgerald set a $41.00 target price on shares of Mylan and gave the company a “hold” rating in a research note on Wednesday, May 9th. Finally, Bank of America decreased their target price on shares of Mylan from $43.00 to $42.00 and set a “neutral” rating for the company in a research note on Tuesday. One analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $46.52.

Mylan Company Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.